^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GTB-3650
i
Other names: GTB-3650, OXS-C3550, Anti-CD16-IL-15-anti-CD33 TriKE
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
GT Biopharma
Drug class:
NK cell stimulant, IL-15R stimulant, CD33 inhibitor
Related drugs:
17d
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
P1, N=45, Not yet recruiting, Masonic Cancer Center, University of Minnesota | Initiation date: Oct 2024 --> Jan 2025
Trial initiation date • Trispecific
|
GTB-3650
2ms
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
P1, N=45, Not yet recruiting, Masonic Cancer Center, University of Minnesota
New P1 trial
|
GTB-3650
2years
A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML (ASH 2022)
In the initial study, the iNK cell backbone (iNK cells without the α3 MICA/B CAR) induced potent activity against the AML cell line HL60, and displayed further enhancement of activity with the addition of anti-CD33 TriKE (GTB-3650), representing combined effects of natural cytotoxicity and antibody-dependent cellular cytotoxicity. Studies with primary AML targets, +/- preincubation of decitabine and all-trans retinoic acid, known to upregulate NKG2D ligands in AML, are in progress and will be discussed. In summary, dual-targeting strategies using off-the-shelf CAR NK cells targeting α3 MICA/B in combination with antigen-specific TriKE targeting CD33 represent an ideal clinical strategy to enhance efficacy and durability of treatment in advanced AML.
Clinical • IO biomarker
|
IL15 (Interleukin 15) • NKG2D (killer cell lectin like receptor K1)
|
decitabine • GTB-3650
Share via
